Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 4Completed 2Unknown 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Solid Tumors 1Colorectal Neoplasms 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × tomivosertib × Clear all
NCT03616834 2023-03-22

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

Effector Therapeutics

Phase 2 Completed
39 enrolled
Other solid neoplasm

Solid Tumors

NCT03258398 2019-07-18

A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer

Effector Therapeutics

Phase 2 Completed
56 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡